Post hoc analysis of a phase III trial (1,007 patients with locally advanced gastric/GEJ adenocarcinoma): pembrolizumab plus chemotherapy raised pCR (13.9% vs 2.8%); among those with major pathologic response, HRs were 0.6 for EFS and 0.7 for OS.
Secondary analysisn = 1,007
Shitara et al. Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma